中山醫學大學機構典藏 CSMUIR:Item 310902500/23652
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17935/22950 (78%)
造访人次 : 7478017      在线人数 : 405
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23652


    题名: Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
    作者: Kuo, WL;Tseng, LL;Chang, CC;Chen, CJ;Cheng, ML;Cheng, HH;Wu, MJ;Chen, YL;Chang, RT;Tang, HY;Hsu, YC;Lin, WJ;Kao, CY;Hsieh, WP;Kung, HJ;Wang, WC
    关键词: O-GlcNAc;PKM2;HR+/HER2(-) luminal breast cancer;metabolism;prognosis
    日期: 2021
    上传时间: 2022-08-05T09:40:44Z (UTC)
    出版者: MDPI
    摘要: Predictive metabolic biomarkers for the recurrent luminal breast cancer (BC) with hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-negative are lacking. High levels of O-G1cNAcylation (O-GlcNAc) and pyruvate kinase isoenzyme M2 (PKM2) are associated with malignancy in BC; however, the association with the recurrence risk remains unclear. We first conduct survival analysis by using the METABRIC dataset to assess the correlation of PKM2 expression with BC clinical outcomes. Next, patients with HR+/HER2(-) luminal BC were recruited for PKM2/O-GlcNAc testing. Logistic regression and receiver operating characteristic curve analysis were performed to evaluate the 10-year DFS predicted outcome. Survival analysis of the METABRIC dataset revealed that high expression of PKM2 was significantly associated with worse overall survival in luminal BC. The high expression of O-GlcNAc or PKM2 was a significant independent marker for poor 10-year DFS using immunohistochemical analysis. The PKM2 or O-GlcNAc status was a significant predictor of DFS, with the combination of PKM2-O-GlcNAc status and T stage greatly enhancing the predictive outcome potential. In summary, O-GlcNAc, PKM2, and T stage serve as good prognostic discriminators in HR+/HER2(-) luminal BC.
    URI: http://dx.doi.org/10.3390/diagnostics11081460
    https://www.webofscience.com/wos/woscc/full-record/WOS:000688909700001
    https://ir.csmu.edu.tw:8080/handle/310902500/23652
    關聯: DIAGNOSTICS ,2021,v11,issue 8
    显示于类别:[中山醫學大學研究成果] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML146检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈